|Bid||0.00 x 1400|
|Ask||0.00 x 800|
|Day's range||22.14 - 23.27|
|52-week range||6.80 - 34.64|
|Beta (5Y monthly)||0.87|
|PE ratio (TTM)||N/A|
|Earnings date||25 Feb 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||32.25|
The Zacks Analyst Blog Highlights: INO, NVAX, TBIO and VXRT
Messenger RNA (mRNA) coronavirus vaccine candidates now appear to be batting two for two. Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) announced great interim efficacy results for their experimental mRNA COVID-19 vaccine last week. Are there other biotech stocks with mRNA vaccine programs that could also be winners?
Sanofi (SNY) and Translate Bio select coronavirus vaccine candidate MRT5500 for clinical development, based on its promising pre-clinical data. A clinical study is anticipated by this year-end.